Germany: German FPC adds another twist to pemetrexed case
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: German FPC adds another twist to pemetrexed case

European patent EP 1 313 508 B1 claims the use of pemetrexed disodium in the manufacture of a medicament for use in a combination therapy together with vitamin B12 for inhibiting tumour growth. In the last six years, several courts throughout Europe have dealt with the question of whether medicaments containing a different salt or the free acid of pemetrexed infringe this patent by equivalent means. Most of the lower courts denied an infringement. However, the supreme courts went in a different direction: the UK Supreme Court (case no. [2017] UKSC 48, judgment of July 12 2017) and the Swiss Federal Supreme Court (case no. 4A_208/2017, judgment of October 20 2017) found infringement under the doctrine of equivalence. The decision of the German Federal Supreme Court (case no. X ZR 29/15, judgment of June 14 2016) was only concerned with one aspect of the doctrine. However, in light of this decision, the German Higher Regional Court of Munich confirmed infringement by equivalent means in its judgment of May 18 2017 (case no. 6 U 3039/16).

In contrast to the numerous infringement proceedings, national court decisions regarding the validity of European patent EP 1 313 508 B1 – which was maintained as granted in the opposition proceedings before the European Patent Office – are rare. In the UK and Swiss proceedings mentioned above, validity was not challenged. Validity was challenged in Germany, but not in the above-mentioned proceedings. Due to the so-called bifurcated system, validity of a patent and patent infringement cannot be dealt with in the same proceedings in Germany. Lack of validity has to be raised in separate proceedings before the German Federal Patent Court (FPC). In July 2018, the FPC revoked the German part of EP 1 313 508 B1 (case no. 3 Ni 23/16 (EP), judgment of July 17 2018). The reasons for this decision were published in November 2018. According to the FPC, the combined use of pemetrexed disodium and vitamin B12 for inhibiting tumour growth is obvious in view of the prior art.

Presently, an appeal is pending before the German Federal Supreme Court. It remains to be seen whether the Federal Supreme Court will confirm the decision of the FPC or add still another twist to the pemetrexed case. Overall, the pemetrexed case with all its twists is reminiscent of a quote attributed to the baseball legend Lawrence Peter "Yogi" Berra: "It ain't over till it's over."

renate-rieder.jpg

Renate Rieder

Maiwald Patentanwalts- und Rechtsanwalts GmbH

Elisenhof, Elisenstr 3

D-80335, Munich, Germany

Tel: +49 89 74 72 660 

Fax: +49 89 77 64 24

info@maiwald.eu

www.maiwald.eu

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article